| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2015-08-664755 |
| P698 | PubMed publication ID | 26508783 |
| P50 | author | Martin Pule | Q39819805 |
| Laurie Menger | Q57419264 | ||
| Sergio A Quezada | Q60622517 | ||
| P2093 | author name string | Stanley R Riddell | |
| Agnes Gouble | |||
| Annette Pachnio | |||
| Jake Y Henry | |||
| Julianne Smith | |||
| Karl S Peggs | |||
| Katharina Bergerhoff | |||
| Maria A V Marzolini | |||
| Paul Moss | |||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| P304 | page(s) | 2781-2789 | |
| P577 | publication date | 2015-10-27 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells | |
| P478 | volume | 126 |
| Q52721827 | Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders. |
| Q96591112 | CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation |
| Q98735538 | Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation |
| Q39272183 | Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective |
| Q38884383 | Chimeric antigen receptors: driving immunology towards synthetic biology |
| Q92700219 | Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients |
| Q39037477 | Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials |
| Q40527248 | Genome Editing in Large Animals. |
| Q33729598 | Genome-Edited T Cell Therapies. |
| Q92700078 | Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients |
| Q39215653 | Immunotherapy for infectious diseases in haematological immunocompromise |
| Q39382670 | Immunotherapy for transplantation-associated viral infections |
| Q40215133 | Parainfluenza Virus 3-Specific T Cells: Opportunity for Intervention? |
| Q37058107 | T cells for viral infections after allogeneic hematopoietic stem cell transplant |
| Q36406966 | Tailoring steroid-sensitive virus-specific T cells with TALEN |
| Q60938384 | The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease |
| Q55260963 | The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay. |
| Q91855845 | To Bridge, Blossom, or Boost: That Is the Question |
| Q38788714 | To CRISPR and beyond: the evolution of genome editing in stem cells |
| Q47108856 | Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing |
| Q38797660 | Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. |
| Q57082741 | Unchaining NK cell–mediated anticancer immunosurveillance |
| Q47603836 | Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT. |
| Q42654381 | Virus-Specific T Cells for the Immunocompromised Patient |
Search more.